Tacrolimus-rapamycin combination therapy for experimental autoimmune uveoretinitis

Area of Science:

• Immunology
• Ophthalmology
• Pharmacology

Background:

• Tacrolimus and rapamycin are novel immunosuppressants belonging to the immunophilin ligand family.
• These drugs inhibit T cell activation through distinct mechanisms.
• Understanding their combined effects is crucial for developing potent immunosuppressive therapies.

Purpose of the Study:

• To evaluate the immunosuppressive effects of combining low-dose tacrolimus and rapamycin.
• To assess the efficacy of this combination therapy in a rat model of experimental autoimmune uveoretinitis (EAU).

Main Methods:

• Male Lewis rats were immunized with S-antigen (S-Ag) to induce EAU.
• Intraperitoneal injections of combined tacrolimus and rapamycin were administered for 14 days post-immunization.
• Efficacy was assessed through clinical observation, histological examination, and measurement of immune responses (serum antibodies and lymphocyte proliferation).

Main Results:

• Combination therapy with low-dose tacrolimus (0.1 mg/kg/day) and rapamycin (0.03 mg/kg/day) resulted in 100% clinical and 66.7% histological suppression of EAU.
• A higher dose of rapamycin (0.1 mg/kg/day) with tacrolimus achieved 100% clinical and histological suppression.
• Monotherapy with either drug alone or doubled doses showed only partial suppression of EAU.
• Combination therapy significantly suppressed serum antibody levels to S-Ag and lymphocyte proliferation.

Conclusions:

• Low-dose combination therapy of tacrolimus and rapamycin demonstrates potent immunosuppressive effects against EAU.
• This combination therapy is more effective than monotherapy in suppressing EAU and related immune responses.
• The findings suggest a promising therapeutic strategy for autoimmune ocular diseases.